IC
JBIO

Ikarian Capital’s Jade Biosciences JBIO Stock Holding History

Ikarian Capital’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29
Closed -$166K – 154
2024
Q2 		$166K Buy
+29
New +$19.2K 0.03% 107

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ikarian Capital's JBIO Position: Q1 2026 in Review

Ikarian Capital increased its Jade Biosciences (JBIO) stake by 71% in Q1 2026, buying an estimated $3.07M and bringing the position to 512,349 shares worth $7.2M. The position accounts for 0.58% of the portfolio, ranked #47.

Ikarian Capital first reported a position in JBIO in Q3 2022 and has held it in 8 quarters since. The position peaked at $10.9M in Q1 2024. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Ikarian Capital held 512,349 shares of Jade Biosciences worth $7.2M as of Q1 2026.
  • Ikarian Capital bought 212,349 Jade Biosciences shares in Q1 2026, an estimated $3.07M.
  • Jade Biosciences made up 0.58% of Ikarian Capital's portfolio in Q1 2026, its #47 holding.
  • Ikarian Capital first reported a position in Jade Biosciences in Q3 2022 and has held it in 8 quarters since.
  • Ikarian Capital's Jade Biosciences position peaked at $10.9M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.